Prostate Cancer - Results from #27920

AUA 2011 - Prostate cancer detection rates, risk factors, and distribution with transperineal mapping template prostate biopsy: initial single institution experience - Session Highlights May 17, 2011

AUA 2011 - Potency outcomes in patients who had multiple biopsies before radical prostatectomy for the treatment of localized prostate cancer - Session Highlights May 17, 2011

AUA 2011 - Evaluation of the prostate health index (PHI) in the 2 to 4, and 4 to 10 ng/ml PSA ranges: Results from a multi-site, prospective, clinical evaluation - Session Highlights May 17, 2011

AUA 2011 - 11C-choline PET/CT versus transrectal ultrasound-guided prostate biopsy to diagnose locally recurrent prostate cancer following radiation therapy - Session Highlights May 17, 2011

AUA 2011 - How soon can we identify men at high risk for prostate cancer death? An early surveillance strategy for prostate cancer - Session Highlights May 17, 2011

AUA 2011 - Smoking linked to biochemical recurrence of prostate cancer - Press Release May 17, 2011

AUA 2011 - Building a better cancer test: Updates on new biomarkers and genetic assays for bladder and prostate cancers - Press Release May 17, 2011

AUA 2011 - Extended sampling biopsies, MRI show promise in managing low-risk prostate cancer - Press Release May 16, 2011

AUA 2011 - Abiraterone demonstrates effective results with favorable safety profile in men with castration-resistant advanced prostate cancer - Press Release May 16, 2011

AUA 2011 - Prostate cancer: To treat, not to treat and when to treat? - Press Release May 16, 2011

AUA 2011 - Clusterin antisense inhibitor OGX-011 synergizes activity of second generation anti-androgen, MDV3100, in castrate resistant prostate cancer model - Session Highlights May 16, 2011

AUA 2011 - Differential expression of RANKL and osteoprotegerin in patients with clinically localized prostate cancer - Session Highlights May 16, 2011

AUA 2011 - Pre-operative urinary prostate cancer gene 3 (PCA3) is predicting pathologically confirmed small volume and insignificant prostate cancer - Session Highlights May 16, 2011

AUA 2011 - Implications of surgical margin status on prostate cancer-specific survival - Session Highlights May 16, 2011

AUA 2011 - Phase 1-2 study of MDV3100 in pre-and post-docetaxel advanced prostate cancer: long-term efficacy results - Session Highlights May 16, 2011

AUA 2011 - Benefit of denosumab therapy in patients with bone metastases from castrate resistant prostate cancer: A number-needed-to-treat (NNT) analysis - Session Highlights May 16, 2011

AUA 2011 - Stromal but not epithelial androgen receptor level is associated with prostate cancer related death - Session Highlights May 16, 2011

AUA 2011 - Neuropeptides promote castration resistant prostate cancer through intracrine androgen biosynthesis - Session Highlights May 16, 2011

AUA 2011 - Androgen independent, tumor-reinitiating cells are selected by androgen deprivation in models of androgen dependent prostate cancer - Session Highlights May 16, 2011

AUA 2011 - Interleukin-6: A potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer - Session Highlights May 16, 2011

Page 1397 of 1434